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ABSTRACT
Neuroblastoma is a pediatric tumor of the sympatoadrenal lineage of the neural 
crest characterized by high molecular and clinical heterogeneity, which are the main 
causes of the poor response to standard multimodal therapy. The identification of new 
and selective biomarkers is important to improve our knowledge on the mechanisms 
of neuroblastoma progression and to find the targets for innovative cancer therapies. 
This study identifies a positive correlation among tropomodulins (TMODs) proteins 
expression and neuroblastoma progression. TMODs bind the pointed end of actin 
filaments, regulate polymerization and depolymerization processes modifying actin 
cytoskeletal dynamic and influencing neuronal development processes. Expression 
levels of TMODs genes were analyzed in 17 datasets comprising different types 
of tumors, including neuroblastoma, and it was demonstrated that high levels of 
tropomodulin1 (TMOD1) and tropomodulin 2 (TMOD2) correlate positively with 
high survival probability and with favorable clinical and molecular characteristics. 
Functional studies on neuroblastoma cell lines, showed that TMOD1 knockin induced 
cell cycle arrest, cell proliferation arrest and a mature functional differentiation. 
TMOD1 overexpression was responsible for particular cell morphology and biochemical 
changes which directed cells towards a neuronal favorable differentiation profile. 
TMOD1 downregulation also induced cell proliferation arrest but caused the loss of 
mature cell differentiation and promoted the development of neuroendocrine cellular 
characteristics, delineating an aggressive and unfavorable tumor behavior. Overall, 
these data indicated that TMODs are favorable prognostic biomarkers in neuroblastoma 
and we believe that they could contribute to unravel a new pathophysiological 
mechanism of neuroblastoma resistance contributing to the design of personalized 
therapeutics opportunities.
INTRODUCTION
Neuroblastoma is an embryonic tumor of the 
peripheral sympathetic nervous system, arising during 
fetal or early postnatal life from sympathetic cells derived 
from the neural crest. It is the most common solid extra 
cranial malignancy of childhood affecting 10.5 per 
million children between 0 and 14 years of age and it is 
responsible for 15% of all cancer-related mortalities in 
children [1, 2]. Neuroblastoma is characterized by a broad 
range of clinical and biological heterogeneity, ranging 
from spontaneous regression or differentiation into benign 
tumors to rapid and aggressive phenotype that does not 
respond to current intensive multimodal therapy. In half 
of cases distant metastasis are detected at diagnosis and 
the tumor is classified as “high-risk” with a survival rate 
lower than 40% [3]. Several gene mutations, deletions or 
chromosomal rearrangements are involved in the onset of 
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neuroblastoma and are associated with poor outcome, such 
as ALK, PHOX2B and MYCN gene amplification [4, 5]. 
Our previous study identified Notch pathway as one of the 
molecular pathways involved in the onset and progression 
of neuroblastoma [6]. In particular, we recognized Notch 
ligand DLL1 as the specific molecular target in childhood 
neuroblastoma and we proposed miRNAs as novel 
therapeutic tool to attack “DLL1 positive” neuroblastoma 
[7]. The challenge is to identify innovative and selective 
biomarkers to better understand clinical and molecular 
mechanisms underlying neuroblastoma progression and 
to devise new personalized therapeutics opportunities. In 
this study we demonstrated a strong correlation between 
TMODs expression and neuroblastoma survival. TMODs 
are a conserved family of 40 kDa proteins that cap actin 
filaments pointed end, stabilize filaments and inhibit their 
disassembly and turnover; they are defined pointed end 
capping protein for actin filaments [8, 9]. There are four 
TMOD isoforms (TMOD1, TMOD2, TMOD3, TMOD4) 
expressed in different tissues in vertebrates encoded by 
distinct genes. TMOD1 and TMOD2 isoforms are the 
only expressed in neurons, TMOD3 is ubiquitous and 
TMOD4 is mainly localized in skeletal muscle cells [10]. 
TMODs interact with a series of cytoskeletal proteins 
and this link allows to modulate the polymerization and 
depolymerization of actin monomers, modifying their 
dynamics and thus to act indirectly on the mechanical 
properties of the cytoskeletal and cellular physiology [11, 
12]. Actin cytoskeletal dynamics play a crucial role in 
neuronal system development and drive important processes 
such as neurite extension, formation of axon, dendrites 
and growth cones migration [13, 14]. Fath and colleagues 
[15] demonstrated, for the first time, that TMOD1 and 
TMOD2 are negative regulators of neurite outgrowth and 
they have a key role in neurites formation and extension. 
TMODs can stabilize actin filaments that are not available 
for the formation of new neurites, or reduce the actin levels 
required for the polymerization. TMODs are also able to 
influence positively dendritic arbor, indeed overexpression 
of both TMOD1 and TMOD2 increased dendritic 
complexity and the branching [16]. Recently, TMODs 
are emerging as new protagonists in several diseases 
pathogenesis; TMOD2 has altered expression in fetal 
Down syndrome [17], mesial temporal lobe epilepsy [18], 
post-stroke [19] and post-methamphetamine exposure [20], 
while TMOD3 has been reported as a novel biomarker with 
high sensitivity and diagnostic accuracy in endometriosis 
[21]. Initial studies reported TMODs role in cancer; Kureha 
and colleagues [22] demonstrated that TMOD1 expression 
was directly regulated by NF-κB and its overexpression was 
associated with enhanced breast tumor growth in a mouse 
xenograft model. TMOD1 is a powerful diagnostic marker 
for ALK-negative anaplastic large-cell lymphoma [23] 
and it was overexpressed frequently in oral squamous cell 
carcinoma [24]. TMOD2 high expression levels correlate 
with high survival probability and favorable disease 
outcome in neuroblastoma patients’ [25], while TMOD3 
up regulation is responsible for chemotherapeutic agents’ 
resistance in non-small cell lung carcinoma [26]. Our data 
clearly demonstrated extensively a positive and specific 
correlation between TMOD1 and TMOD2 expression 
levels and neuroblastoma; high expression levels of these 
two genes were associated with high survival probability 
and good prognosis of neuroblastoma patients’. In vitro 
characterization and functional studies led us to better 
understand the role of TMOD1 in neuroblastoma cell lines. 
In particular, we identified that TMOD1 knockin caused 
cell cycle arrest, cell proliferation arrest in addition to a 
functional and mature cell differentiation. On the contrary, 
TMOD1 knockdown induced loss of expression of mature 
neuronal markers and the production of an unfavorable cell 
differentiation profile.
RESULTS
TMOD1 and TMOD2 high expression levels 
are associated with high survival probability 
neuroblastoma patients’
We assessed the expression of TMOD1 and TMOD2 
genes in 17 different datasets comprising different types 
of tumors and we added an additional neuroblastoma 
dataset as control (Supplementary Table 1). We found 
that TMODs expression varied among tumor types but 
the highest expression of TMOD1 (Figure 1A) and 
TMOD2 (Figure 1B) was observed in neuroblastoma 
tumors (Bonf p<0.01). We have not found a significant 
difference of expression for either genes between the 
two neuroblastoma datasets supporting the conclusion 
that either genes are highly expressed in neuroblastoma 
(p>0.05, Figure 1A and 1B). These findings raised the 
question of the prognostic significance of these genes. 
We studied the survival curves of 498 neuroblastoma 
patients split in high or low TMODs expression. We 
found that 440 patients with high TMOD1 expression 
had a good overall survival (5y-OS±SE: 0.82±0.02%) 
as opposed to 58 patients with low TMOD1 expression 
levels who had a poor overall survival (5y-OS±SE: 
0.44±0.07) (Figure 1C). Likewise, 397 patients with high 
expression levels of TMOD2 had a good overall survival 
(5y-OS±SE: 0.86±0.01) as opposed to 101 patients with 
low TMOD2 expression levels who had a poor overall 
survival (5y-OS±SE: 0.45±0.05%) (Figure 1D). Overall 
survival between low and high expression of TMODs was 
significantly different (TMOD1 HR 0.27 95%CI 0.06-
0.23 and TMOD2 HR 0.19 95%CI 0.04-0.13 both Bonf 
p<0.0001). These results demonstrated that TMODs were 
prognostic and that good prognosis was associated with 
high expression levels. We confirmed the observation 
that TMOD1 and TMOD2 stratified patients into groups 
with different overall survival (TMOD1 HR 0.15 95%CI 
0.02-0.14, and TMOD2 HR 0.06 95% CI 0.02-0.1, both 
Oncotarget27094www.oncotarget.com
Bonf p<0.0001 and TMOD1 HR 0.2 95% CI 0.01-0.2, and 
TMOD2 HR 0.2 95% CI 0.06-0.3, both Bonf p<0.0001), 
and that high expression levels of TMOD1 and TMOD2 
were associated with good prognosis on two independent 
datasets of 88 neuroblastoma primary tumors profiled 
by Affymetrix platform and 251 neuroblastoma primary 
tumors profiled by customized 11K oligonucleotide-
microarrays (Supplementary Figure 1). Analysis of the 
relationship between TMODs expression and known 
neuroblastoma risk factors indicated that TMODs 
maintained a significant prognostic value when the model 
was adjusted for the clinical and molecular covariates 
(TMOD1 OS HR 0.4 95% CI 0.2-0.7 and TMOD2 HR 
0.5; 95% CI 0.2-0.8, both p≤0.01) (Supplementary 
Table 2) demonstrating that TMODs expression is an 
independent risk factors for neuroblastoma patients. 
Accordingly, TMOD1 and TMOD2 expression was 
significantly higher in low risk than in high risk patients. 
Higher TMODs expression was observed in patients with 
less than 18 months of age at diagnosis (p<0.01; Figure 
2A), in stage I, II, III, IVs tumors (p<0.01; Figure 2B) 
and in MYCN single copy tumors (p<0.01; Figure 2C). 
These findings were confirmed in an independent dataset 
(Supplementary Figure 2) supporting the conclusion that 
TMODs expression is elevated in patients with favorable 
clinical and molecular characteristics.
TMODs have different expression levels 
and cellular localization in differentiated 
neuroblastoma cells
Neuroblastoma patients’ data identified a positive 
correlation among TMODs high expression levels, good 
survival probability and favorable prognosis. On this 
basis, we investigated the role of TMODs in vitro on the 
biology of neuroblastoma cell lines. First, we evaluated 
the presence and the expression levels of TMOD1 and 
TMOD2 in SH-SY5Y and SK-N-SH neuroblastoma cells. 
Proteins and mRNA expression levels were studied in 
untreated and 13-cis retinoic acid treated cells, currently 
used in neuroblastoma therapy as cell-differentiating 
agent in association with standard therapeutic protocols 
[27]. Neuroblastoma cells were cultured for 72 hours 
after 13-cis retinoic acid treatment and then analyzed by 
Western Blotting and qRT-PCR. We observed, in both 
cell lines, that TMOD1 expression was barely detectable 
in the control group and significantly increased after 
13-cis retinoic acid treatment; instead, TMOD2 protein 
expression level was present in untreated cells and did 
not increase after 13-cis retinoic acid treatment (Figure 
3A, 3B). These results are in agreement with the study 
of Fath and colleagues [15] in N2a neuroblastoma cells. 
To better-characterize TMODs behaviour, we studied the 
localization of these two proteins in neuroblastoma cell 
lines by immunocytochemistry. Staining TMODs in both 
cell lines, it emerged that TMOD1 has a cytoplasmic 
localization and it is expressed all along the cell neurites, 
while TMOD2 has a mainly perinuclear localization 
(Figure 3C).
TMOD1 knockin induces cell cycle arrest in G0/
G1 phase and cell proliferation arrest
Since both TMODs correlate positively with 
neuroblastoma and only TMOD1 expression levels 
increased significantly after 13-cis retinoic acid treatment, 
we decided to investigate the effects of TMOD1 
overexpression in neuroblastoma cell lines measured by 
cell cycle, proliferation and cell differentiation parameters. 
For cell cycle analysis, neuroblastoma cell lines were 
transfected with GFP-TMOD1 plasmid for 72 hours at 
three different concentrations (1 μg/μl, 5 μg/μl, 10 μg/μl). 
Flow cytometry analysis showed that TMOD1 knockin 
induced cell cycle arrest in G0/G1 phase (Figure 4A). 
In particular, there was a significant increase in the cells 
number in G0/G1 phase and a decrease of cells number in 
S phase cell cycle, compared to control. The data indicated 
that, in both cell lines, TMOD1 knockin blocked cells 
in G0/G1 phase decreasing the tumor cells number in 
proliferation. The cell proliferation arrest was evaluated 
also by immunocytochemistry using cell proliferation 
marker Ki-67; TMOD1 knockin induced a significant 
cell proliferation arrest, in a dose dependent manner, 
with a decrease in the number of Ki-67 nuclei positive 
cells compared to the control (Figure 4B). A quantitative 
analysis of cell proliferation arrest was obtained by 
counting the number of Ki-67 nuclei positive cells in a 
minimum of 10 fields for each treatment (Figure 4C). A 
direct nuclei cell count was also performed confirming a 
significant reduction of cells number induced by TMOD1 
knockin compared to the control (mean cell number/field 
± S.E.M.: 70.0 ± 8.375 for control, 48.38 ± 3.343 for 
TMOD1 1μg/μl, 45.80 ± 6.996 for TMOD1 5 μg/μl, 29.80 
± 6.689 for TMOD1 10 μg/μl).
TMOD1 knockin induces in neuroblastoma cells 
a neuron-like differentiated profile
Cells differentiation was analyzed in both cell 
lines by immunocytochemistry and representative 
images by confocal microscopy showed that TMOD1 
knockin induced neuroblastoma cells differentiation 
characterized by long neurites with sprouting, growth 
cones and varicosities (Figure 5A). Neurites arborization 
and the formation of varicosities are the main features 
of functional and mature cell differentiation [28–30]. It 
was investigated in detail the biochemical implications 
of cell differentiation induced by TMOD1 knockin by 
evaluating the expression levels of a set of differentiation 
markers. qRT-PCR analysis showed a significant increase 
of neuronal markers such as Microtubule-associated 
protein 2 (MAP2) and Growth Associated protein 43 
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(GAP43) (Figure 5B), while Tyrosine hydroxylase (TH), 
Dopamine beta-hydroxylase (DBH) and Chromogranin 
A (CgA) showed a decrease in mRNA expression levels 
(Figure 5C). MAP2 and GAP43 proteins are involved in 
neurogenesis and their expression is indicative of neuronal 
growth, development and stabilization. In conclusion, the 
morphological and biochemical data collected suggested 
that TMOD1 overexpression induced the development of 
a neuronal cell differentiation profile.
TMOD1 knockdown induces in neuroblastoma 
cells a neuroendocrine differentiation profile
To further examine the TMOD1 functional role in 
neuroblastoma cells, we studied the effects of TMOD1 
downregulation utilizing RNA interference technique. 
TMOD1 downregulation, as occur with TMOD1 
overexpression, induced both cell cycle and proliferation 
arrest (data not shown), but surprisingly it induced a new 
differentiation profile characterized by long and thin 
neurites, without sprouting, growth cones and varicosities 
(Figure 6A). The cell differentiation observed was 
very different compared to that obtained after TMOD1 
overexpression. To better understand the nature of this 
type of differentiation, we evaluated the expression of a 
set of differentiation markers by qRT-PCR. After TMOD1 
knockdown, Microtubule-associated protein 2 (MAP2) 
mRNA expression levels remained unchanged while there 
was a decrease of Growth Associated protein 43 (GAP43) 
neuronal marker (Figure 6B). Conversely, a significant 
Figure 1: TMOD1 and TMOD2 genes are more expressed in neuroblastoma than in other tumors types and their 
high expression levels correlate with a good overall survival. The box and whisker plots show the expression of TMOD1 (A) 
and TMOD2 (B) in 18 different data sets. Red and blue boxes and whiskers refer to the neuroblastoma and other tumor types datasets, 
respectively. The box and whisker are sorted by decreasing order of median expression value. Plots are entitled with ANOVA p value and 
the corresponding gene symbol. The Bonferroni (Bonf) adjusted p value obtained by post-hoc analysis is reported below the black bar. We 
considered significant a p value<0.05. Kaplan-Meier curves show overall survival in the 498 patients’ cohort stratified by TMOD1 (C) and 
TMOD2 (D). Plots are entitled with the corresponding gene symbol. High expression (blue) and low expression (red) curves were compared 
by log-rank test and corrected for multiple hypotheses testing by Bonferroni method. Each plot reports the Bonferroni corrected p value 
(Bonf), the hazard ratio and confidence interval of the stratification. HR: hazard ratio. CI: confidence interval. ns: not significant.
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Figure 2: TMOD1 and TMOD2 expression levels correlate with favorable clinical and molecular characteristics. Box 
and whisker plots of TMOD1 and TMOD2 in the populations defined by Age at diagnosis (A), INSS stage (B) and MYCN status (C) risk 
factors. Data are relative to the patients in the 88 patients’ cohort. Plots are entitled with the corresponding gene symbol. Significance of the 
difference between the means has been assessed by unpaired t test. A probability smaller than 0.05 was considered a significant difference. 
** means p<0.001, *** means p<0.0001 and **** means p<0.00001. Age at diagnosis (≤ 18 months (blue) vs. > 18 months (red)), INSS stage 
(I, II, III, IVs (blue) vs. IV(red)) and MYCN status (single copy (blue) vs. amplified (red)) groups define the clinical and molecular sub-
populations.
Figure 3: TMOD1 and TMOD2 have different expression levels and cellular localization in neuroblastoma cell lines. 
(A) Western Blotting analysis of TMOD1 and TMOD2 protein expression levels in SH-SY5Y and SK-N-SH untreated and 13-cis retinoic 
acid treated cells. GAPDH was used as a loading control. Densitometric analysis of TMOD1 and TMOD2 protein expression levels was 
obtained using Image Studio™ Software- LI-COR System. (B) qRT-CR analysis of TMOD1 and TMOD2 mRNA expression levels in SH-
SY5Y and SK-N-SH untreated and 13-cis retinoic acid treated cells. Data are normalized to the GAPDH signal and are obtained from three 
experiments. * means p<0.05 vs. control. (C) Representative confocal images of SH-SY5Y neuroblastoma cells after 72 hours in culture 
medium alone (Ctr) or in medium added 40 μM 13-cis retinoic acid. TMOD1 and TMOD2 antibodies were in green, β III tubulin antibody 
was in red and Hoechst, used as nuclei marker, was in blue. Merge represents the superposition of the three signals. Scale bar, 40 μm.
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Figure 4: TMOD1 knockin induces cell cycle and cell proliferation arrest. (A) Cell cycle analysis of SH-SY5Y and SK-N-SH 
neuroblastoma cells transfected with GFP-TMOD1 plasmid for 72 hours with three different concentrations (1 μg/μl, 5 μg/μl, 10 μg/μl). 
*means p<0.0001 vs. G0/G1 phase control; ** means p<0.0001 vs. S phase control; *** means p<0.0001 vs. G2/M phase control. Data are 
obtained from three experiments. (B) Representative confocal images of SH-SY5Y neuroblastoma cells transfected with GFP-TMOD1 
plasmid for 72 hours. Ki-67, proliferation marker, was in green, β III tubulin antibody was in red and Hoechst, used as nuclei marker, 
was in blue. Merge represents the superposition of the three signals. Scale bar, 40 μm. (C) Quantitative analysis of proliferation cells was 
determined by counted the number of Ki-67 nuclei positive cells at least 10 fields for each treatment. * means p<0.001 vs. control.
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increase of Tyrosine hydroxylase (TH), Dopamine beta-
hydroxylase (DBH), and Neuron-specific enolase (NSE) 
was observed (Figure 6C). In particular, we observed a 
significant increase of Chromogranin A (CgA) mRNA 
expression levels (Figure 6D), a neuroendocrine secretory 
protein, which is a useful prognostic and diagnostic tool 
for neuroblastoma and correlates with tumor burden 
and survival patients’ [31]. These data suggest that 
TMOD1 downregulation induced the loss of neuron-like 
differentiated profile towards neuroendocrine profile.
DISCUSSION
The understanding of biological mechanisms 
and biomarkers involved in the onset and progression 
of neuroblastoma is needed to reach better prognostic 
stratification and more efficacious therapeutic strategies. 
In the present study, we demonstrated that TMOD1 
and TMOD2 expression are independent prognostic 
markers and that high expression levels of these genes 
are associated with favorable outcome. Little is known 
about the relationship between neuroblastoma and 
TMOD genes. TMOD2 is part of a 160 gene signatures 
predicting neuroblastoma outcome [32] and of a 55 
gene signature predicting neuroblastoma outcome in 
metastatic neuroblastoma lacking MYCN amplification 
[33]. There is no evidence of studies on TMOD1 and 
neuroblastoma. TMOD1 and TMOD2 were highly 
expressed in neuroblastoma, relative to other tumor 
types, suggesting an important role of these genes in 
the tumor homeostasis. Moreover, both genes showed 
a strong association between high expression and 
favorable neuroblastoma prognosis. The strength of 
this result relies on the large number of samples in the 
three neuroblastoma patients’ datasets (837 tumor 
samples) that have been used to reach this conclusion; 
Figure 5: TMOD1 knockin induces in neuroblastoma cells a neuron-like differentiated profile. (A) Representative confocal 
images of SH-SY5Y neuroblastoma cells transfected with GFP-TMOD1 plasmid at the concentration of 10 μg/μl for 72 hours. TMOD1 
was in green, β III tubulin antibody was in red and Hoechst, used as nuclei marker, was in blue. Merge represents the superposition of the 
three signals. Arrow indicates neurite branching and varicosities. Scale bar, 40 μm. (B) qRT-PCR analysis of MAP2 and GAP43 mRNA 
expression levels in SH-SY5Y untreated and GFP-TMOD1 plasmid transfected cells. (C) qRT-PCR analysis of TH, DBH and CgA mRNA 
expression levels in SH-SY5Y untreated and GFP-TMOD1 plasmid transfected cells. Data are normalized to the GAPDH signal and are 
obtained from three experiments. * means p<0.05 vs. control.
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this conclusion was further supported by the observation 
that newborn patients, no MYCN amplification, or low 
grade stage had a higher expression of TMOD1 and 
TMOD2 in two independent datasets. In vitro functional 
studies demonstrated that TMOD1 knockin induced cell 
cycle arrest in G0/G1 phase, cell proliferation arrest, a 
functional and mature neuron-like differentiation. The 
biochemical differentiation profile of neuroblastoma cells 
overexpressing TMODs showed a significant increase 
of MAP2 and GAP43, mimicking then the “neuronal 
differentiation” obtained by retinoic acid, and an overall 
decrease of TH, DBH and CgA mRNA expression levels. 
On the contrary, TMOD1 downregulation caused the 
loss of mature and functional differentiation cell profile, 
with the appearance of long and thin neurites without 
sprouting and varicosities, the accumulation sites of the 
secretory vesicles of neurotransmitters that are released in 
response to neurosecretory stimuli [29, 30]. Biochemical 
analysis evidenced a decrease of neuronal biomarkers 
expression and a significant increase of TH, DBH, NSE 
and CgA, indexes of neuroendocrine differentiation 
and considered unfavorable prognostic neuroblastoma 
biomarkers [34]. In a recent study, Lee and colleagues 
[35] evaluated the clinical significant of TH mRNA 
transcripts levels in the peripheral blood of patients 
with neuroblastoma demonstrating that TH expression 
was associated with high-risk features, advanced stage 
and worse outcome. Previous studies also reported that 
positive TH expression was a poor prognostic indicator 
in metastatic neuroblastoma [36, 37], suggesting a role of 
this marker in stratification. In particular we observed an 
increase of NSE by tenfold and CgA mRNA expression 
Figure 6: TMOD1 knockdown induces in neuroblastoma cells a neuroendocrine differentiation profile. (A) Representative 
confocal images of siRNA 5 TMOD1 downregulation effects in SH-SY5Y neuroblastoma cells after 72 hours of transfection. TMOD1 was 
in green, β III tubulin antibody was in red and Hoechst, used as nuclei marker, was in blue. Merge represents the superposition of the three 
signals. Arrow indicates thin neurite without varicosities. Scale bar, 40 μm. (B) qRT-PCR analysis of MAP2 and GAP43 mRNA expression 
levels in SH-SY5Y untreated and TMOD1 knockdown treated cells. (C) qRT-PCR analysis of TH, DBH and NSE mRNA expression 
levels in SH-SY5Y untreated and TMOD1 knockdown treated cells. (D) qRT-PCR analysis of CgA mRNA expression levels in SH-SY5Y 
untreated and TMOD1 knockdown treated cells. Data are normalized to the GAPDH signal and are obtained from three experiments. * 
means p<0.05 vs. control.
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sixty-fold higher than control. CgA is a pro-hormone 
that is stored in the same vesicles and co-released with 
catecholamines in adrenal medulla and postganglionic 
sympathetic axons and regulates in turn chatecolamines 
secretion with a negative feedback mechanism [38]. NSE 
and CgA expression correlate with the differentiation level 
of the tumor, metastatic sites and response to treatment; 
patients in stage I and stage II have low levels of CgA and 
favorable outcome, while patients with advanced disease 
stages (III and IV) have high levels of NSE and CgA and 
bad prognosis [39, 40]. Furthermore hypoxia, validated 
as predictor of poor outcome in neuroblastoma, was 
found to induce a shift from neuronal to chromaffin cell 
differentiation, with high expression of neuroendocrine 
markers and decrease in neuronal markers as GAP43 
[41]. Finally, GSK inhibitors were found to arrest 
neuroblastoma cells proliferation coupled with a decrease 
in neuroendocrine markers [42]. Thus, in our experimental 
data, TMOD1 knockdown induced high expression levels 
of all unfavorable neuroendocrine biomarkers, delineating 
an aggressive tumor profile. In conclusion, TMODs are 
able to influence positively survival probability and 
prognosis of neuroblastoma patients mainly acting on cell 
differentiation. Sympathetic neurons and chromaffin cells 
derive from a common fate-restricted sympathoadrenal 
progenitor of the neural crest, which, in response to the 
local environment and a network of transcription factors, 
can choose one or the other differentiation path [43]. Thus, 
TMODs could represents, in prenatal and early post-
natal development, a signal for the correct differentiation 
of sympathetic cells. Although further investigation is 
required, these data identify a new pathway involved in 
neuroblastoma and therefore new strategies will develop 
to tackle the tumor.
MATERIALS AND METHODS
Gene expression datasets
Three publically available datasets were used for gene 
expression analysis. The first dataset [44] contains the gene 
expression profile of 498 neuroblastomas measured by the 
Illumina HiSeq 2000 RNAseq platform (GSE62564). The 
second one [45] contains the gene expression profile of 88 
tumors measured by the Affymetrix Human Genome U133 
Plus 2.0 platform (GSE16476). The third one [Customized 
oligonucleotide microarray gene expression-based 
classification of neuroblastoma patients outperforms current 
clinical risk stratification. Journal of Clinical Oncology, 
24, 5070–5078] contains the gene expression profile of 
251 tumors generated as dye-flipped dual-color replicates 
using customized 11K oligonucleotide-microarrays 
(E-TABM-38). In addition, we utilized 3929 publically 
available expression profiles from 17 different tumor types 
by the Affymetrix Human Genome U133 Plus 2.0 platform 
and stored in the R2: Genomic Analysis and Visualization 
Platform (http://r2.amc.nl). Good and poor outcome were 
defined as the patient’s alive or dead status 5 years after 
diagnosis.
Cell culture
The human SH-SY5Y neuroblastoma cell line 
was cultured in a 1:1 mixture of Ham’s F12 nutrient and 
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) 
supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich), 2 mM L-glutamine, 50 mg/mL penicillin, and 
100 mg/mL streptomycin (Sigma-Aldrich). The SK-N-
SH neuroblastoma cell line was cultured in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich) supplemented 
with 10% fetal bovine serum (FBS, Sigma-Aldrich), 2 
mM L-glutamine, 50 mg/mL penicillin, and 100 mg/
mL streptomycin (Sigma-Aldrich). All the cell lines 
were grown at 37°C in a 95% air–5% CO2 humidified 
incubator. Cell lines, at passage lower than 10, were used 
within 3 months after receipt. Cells supplied by ECACC, 
the European Collection of Authenticated Cell Cultures, 
undergo quality control and authentication procedures. 
These include testing for mycoplasma by culture 
isolation, Hoechst DNA staining and PCR, together 
with culture testing for contaminant bacteria, yeast and 
fungi. Authentication procedures used include species 
verification by DNA barcoding and identity verification 
by DNA profiling. Human cell lines are analyzed by PCR 
of short tandem repeat sequences within chromosomal 
microsatellite DNA (STR-PCR).
13-cis Retinoic acid treatment
Twenty-four hours after seeding in complete media, 
neuroblastoma cell lines were cultured with 40 μM 13-
cis retinoic acid (Sigma-Aldrich). At 80% confluence, 
after 72 hours, cells were collected and proteins were 
extracted for Western Blotting analysis or fixed for 
immunofluorescence and morphologic analysis.
DNA plasmid amplification and transient 
transfection
GFP-TMOD1 plasmid was processed with 
bacterial transformation and amplification. The GFP-
TMOD1 plasmid was purified by Plasmid Midiprep 
Kit (Sigma-Aldrich), according to the manufacturer’s 
protocol. SH-SY5Y and SK-N-SH neuroblastoma 
cell lines were transfected with the plasmid, at three 
different concentrations, using Lipofectamine reagent 
2000 (Invitrogen). The complete process is indicated in 
Supplementary Materials and Methods.
siRNA transient transfection
The human-specific TMOD1 interference was 
performed assessing the efficacy of four different siRNAs 
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at different concentrations to evaluate which siRNA 
was able to induce a greater downregulation of TMOD1 
mRNA expression levels (Supplementary Figure 3). 
SH-SY5Y and SK-N-SH neuroblastoma cell lines were 
transfected with siRNA 5 at the concentration of 10 nM 
using Hi-perfect transfection reagent (Qiagen) in culture 
medium 1 day after seeding. Cells were cultured for 72 
hours after transfection with siRNA 5 and then collected 
for the mRNA expression levels analysis.
RNA extraction and quantitative RT- PCR
The total RNA was isolated from SH-SY5Y and 
SK-N-SH neuroblastoma cells using the RNeasy kit 
(Qiagen) and digested with the RNase-Free DNase set 
(Qiagen), according to the manufacturer’s protocol. RNA 
was retrotranscribed using murine leukemia virus reverse 
transcriptase (Promega Italia) and oligo (dT) 15-18 as a 
primer. Quantitative RT-PCR (qRT-PCR) was performed 
by the SYBR Green I system (BioRad Italy) and detection 
were performed with the ViiA7TM RT-PCR System 
(Applied Biosystems). Primers and complete protocol are 
indicated in Supplementary Materials and Methods.
Western blotting
Total cell lysates were prepared by scraping the cells 
in lysis buffer. 15 μg of total proteins were electrophoresed 
into 10% SDS-PAGE precast gel, transferred to 
nitrocellulose paper, and stained with the antibodies of 
interest, followed by the appropriate secondary antibodies. 
Antibodies and full protocols are listed in Supplementary 
Materials and Methods.
Immunofluorescence analysis
Neuroblastoma cells were plated with a density 
of 75 × 103/well in a 24 wells plate, fixed in ice-cold 
methanol, washed and incubated in Phosphate Buffered 
Saline and Bovine Serum Albumin. Cells were stained 
with the primary antibodies of interest, overnight at 4°C, 
followed by the secondary antibodies conjugated with 
Alexa Fluor® 488 or CY™3. Antibodies and full protocols 
are listed in Supplementary Materials and Methods.
Flow cytometry analysis
For cell cycle analysis, cells were harvested at the 
completion of the siRNA 5 TMOD1 and GFP-TMOD1 
transfections and washed with phosphate-buffered saline 
(PBS; pH 7.4) before being fixed with 70% ethanol on the 
wheel for 15 minutes at 4°C. Subsequently, the cells were 
centrifuged at 4500 rpm for 5 minutes at 4°C, washed with 
phosphate-buffered saline and cells were resuspended in 
600 μl of 0,1% sodium citrate (Sigma-Aldrich), 50 μg/
ml of propidium iodide (PI, Sigma-Aldrich) and 10 μg/ml 
of Ribonuclease A (Sigma-Aldrich) for staining cellular 
DNA. The cellular DNA content was then analyzed using 
a MACS Quant Flow Cytometer (Miltenyi Biotech). Data 
analysis was carried out using FlowJo software V10.
Bioinformatics and statistical analysis
Log2-transformed gene expression values were 
utilized whenever possible. Gene symbol was selected 
as reference annotation. In the Affymetrix platform the 
highest probe set expression was associated to the gene 
symbol [45]. Analysis was carried out, in part by the R2: 
Genomic Analysis and Visualization Platform (http://
r2.amc.nl). Patients overall survival (OS) was assessed by 
Kaplan-Meier curves. Survival probability was reported 
as 5-years overall survival ± standard error (5y-OS±SE). 
Log-rank test, corrected for multiple hypotheses testing 
by the Bonferroni method, assessed the significance of the 
separation between survival curves. Multivariate analysis 
with a Cox proportional regression model evaluated the 
relationship among prognostic factors. The validity of the 
proportional hazards assumption was tested via evaluation 
of scaled Schoenfeld residuals. The significance of the 
difference between mean values was determined by paired 
or unpaired t-test or by ANOVA Kruskal-Wallis test when 
the comparison involved more than two groups with 
significantly different standard deviation.
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